This week we respond to some listener feedback from Dr. Christopher Booth and use it to talk about how to be the best hematologist-oncologist. We also discuss the SADAL study on Selinexor for patients with relapsed refractory diffuse large B-cell lymphoma, as published in The Lancet Haematology.
Finally, we interview Drs. Eva Katsoulakis and Michael Kelley on their recent paper out in the Journal of Clinical Oncology: Precision Oncology, titled "Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program".

Selinexor: doi.org/10.1016/S2352-3026(20)30120-4
Annotation Services: doi.org/10.1200/PO.19.00118

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: https://www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

2.59 The Best Doctor, Selinexor, & Annotation Services for NGS with Drs. Katsoulakis and Kelley

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

2.59 The Best Doctor, Selinexor, & Annotation Services for NGS with Drs. Katsoulakis and Kelley

Download our free app to listen on your phone